Serum chromogranin-A in advanced prostate cancer

BJU International

Volumn 88, Issue 7, 2001, Pages 790-796

  Ferrero Pous M ^a   Hersant, A M ^a   Pecking, A ^a   Bresard Leroy M ^b   Pichon, M F ^a  

^a CENTRE RENÉ HUGUENIN   (France)

^b CIS Bio International   (France)

Author keywords

Advanced prostate cancer; Chromogranin A; Neurone specific enolase; PSA

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTINEOPLASTIC AGENT; CHROMOGRANIN A; ENOLASE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CONTROLLED STUDY; DISEASE MARKER; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE SURGERY; PROTEIN BLOOD LEVEL; RADIOISOTOPE THERAPY; TESTOSTERONE BLOOD LEVEL;

ANTINEOPLASTIC AGENTS, HORMONAL; CHROMOGRANIN A; CHROMOGRANINS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PHOSPHOPYRUVATE HYDRATASE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE-PHOSPHATASE; ROC CURVE; SENSITIVITY AND SPECIFICITY; TESTOSTERONE;

EID: 0035788452     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-4096.2001.001223.x     Document Type: Article

References (31)

1. Di Sant'Agnese PA, de Mesy Jensen KL. Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol 1987; 18: 849-56
2. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999; 6: 503-19
3. Di Sant'Agnese PA, Cockett AT. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996; 78: 357-61
4. Plonowski A, Nagy A, Schally AV, Sun B, Groot K, Halmos G. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. Int J Cancer 2000; 88: 652-7
5. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 1996; 28: 98-106
6. Gkonos PJ, Krongrad A, Roos BA. Neuroendocrine peptides in the prostate. Urol Res 1995; 23: 81-7
7. Bonkhoff H, Stein U, Welter C, Remberger K. Differential expression of the pS2 protein in the human prostate and prostate cancer: Association with premalignant changes and neuroendocrine differentiation. Hum Pathol 1995; 26: 824-8
8. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin A concentrations in prostatic carcinoma. J Urol 1991; 146: 358-61
9. Tarle M, Rados N. Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: Comparative study of a multiple tumor marker assay. Prostate 1991; 19: 23-33
10. Hoosein NM, Logothetis CJ, Chung LW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993; 149: 1209-13
11. Nakada SY, Di Sant'Agnese PA, Moynes RA et al. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 1993; 5: 1967-70
12. Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic and neoplastic human prostate. Virchows Arch Pathol Anat Histopathol 1993; 423: 291-4
13. Tarle M, Frkovic-Grazio S, Kraljié I, Kovacic K. A more objective staging of advanced prostate cancer. Routine recognition of malignant endocrine structures: The assessment of serum TPS, TPSA and NSE values. Prostate 1994; 24: 143-8
14. Cussenot O, Villette JM, Valeri A et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996; 155: 1340-3
15. Wu JT, Astill ME, Liu GH, Stephenson RA. Serum chromogranin A. Early detection of hormonal resistance in prostate cancer patients. J Clin Laboratory Anal 1998; 12: 20-5
16. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res 1999; 59: 3821-30
17. Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000; 6: 1882-90
18. Porter AT, McEwan AJ, Powe JE et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-13
19. Hsiao RJ, Mezger MS, O'Connor DT. Chromogranin A in uremia. Progressive retention of immunoreactive fragments. Kidney Intern 1990; 37: 955-64
20. Degorce F, Goumon Y, Jacquemart L et al. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br J Cancer 1999; 79: 65-71
21. Lewington VJ, McEwan AJ, Ackery DM et al. A prospective randomized double blind crossover study to examine the efficacy of strontium 89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27: 954-8
22. Baudin E, Gigliotti A, Ducreux M et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998; 78: 1102-7
23. Sokoloff RL, Norton KC, Wolfert RL, Rittenhouse HG, Deftos LJ. Serum chromogranin A and TPSA-forms in early stage, untreated prostate cancers. J Urol 1996; 155: A1539
24. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjolnerod OK, Wadum HL. Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997; 30: 1-6
25. Deftos LJ, Nakada S, Burton DW et al. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 1996; 48: 58-62
26. Kimura N, Hoshi S, Takahashi M, Takeha S, Shizawa S, Nagura H. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol 1997; 157: 565-8
27. Tarle M. Serum chromogranin A in monitoring metastatic prostate cancer patients. Anticancer Res 1999; 19: 5663-6
28. Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 1999; 26: 407-21
29. Burchardt T, Burchardt M, Chen MW et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999; 162: 1800-5
30. Mertens WC, Porter AT, Reid RH, Powe JE. Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: A preliminary report. J Nucl Med 1992; 33: 1437-43
31. Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet 2000; 355: 1428-9